Literature DB >> 10050053

Subtilisin-like proprotein convertases, PACE4 and PC8, as well as furin, are endogenous proalbumin convertases in HepG2 cells.

K Mori1, A Imamaki, K Nagata, Y Yonetomi, R Kiyokage-Yoshimoto, T J Martin, M T Gillespie, M Nagahama, A Tsuji, Y Matsuda.   

Abstract

Serum albumin is synthesized as a larger precursor form, proalbumin, which undergoes proteolytic processing at a dibasic site by a hepatic proprotein convertase within the secretory pathway to generate the mature form. Although furin, a member of the subtilisin-like proprotein convertase (SPC) family, was thought to be the only candidate hepatic convertase for proalbumin, SPC family members other than furin were recently suggested to also be involved in proalbumin processing. This study was designed to identify the endogenous proprotein convertases involved in proalbumin processing. Since human hepatoma HepG2 cells are highly differentiated and produce major plasma proteins, this cell line was used as a model for hepatocytes. Northern blot analysis revealed that PACE4, furin and PC8 of the SPC family were expressed in HepG2 cells as well as in the liver. Ribonuclease protection assay showed that PACE4A-II mRNA is the major transcript in HepG2 cells among the PACE4 isoforms. The coexpression studies showed that furin, PACE4A-II and PC8 were all able to convert proalbumin to albumin correctly. To elucidate the roles of these endogenous SPC family members in proalbumin processing, the antisense RNA for PACE4, furin and PC8 was stably expressed in HepG2 cells, respectively. The expression of each antisense RNA resulted in approximately 30% inhibition of endogenous proalbumin processing. We therefore concluded that PACE4 and PC8, as well as furin, are involved in the processing of proalbumin in HepG2 cells, and that these SPC family members are functionally redundant in this processing.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10050053     DOI: 10.1093/oxfordjournals.jbchem.a022329

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  7 in total

1.  The shed ectodomain of type XIII collagen affects cell behaviour in a matrix-dependent manner.

Authors:  Marja-Riitta Väisänen; Timo Väisänen; Taina Pihlajaniemi
Journal:  Biochem J       Date:  2004-06-15       Impact factor: 3.857

2.  A proteomic approach reveals transient association of reticulocalbin-3, a novel member of the CREC family, with the precursor of subtilisin-like proprotein convertase, PACE4.

Authors:  Akihiko Tsuji; Yayoi Kikuchi; Yukimi Sato; Shizuyo Koide; Keizo Yuasa; Masami Nagahama; Yoshiko Matsuda
Journal:  Biochem J       Date:  2006-05-15       Impact factor: 3.857

3.  Estrogen stimuli promote osteoblastic differentiation via the subtilisin-like proprotein convertase PACE4 in MC3T3-E1 cells.

Authors:  Hyejin Kim; Atsushi Tabata; Toshifumi Tomoyasu; Tomomi Ueno; Shigeto Uchiyama; Keizo Yuasa; Akihiko Tsuji; Hideaki Nagamune
Journal:  J Bone Miner Metab       Date:  2014-02-21       Impact factor: 2.626

4.  Proprotein convertase PACE4 is down-regulated by the basic helix-loop-helix transcription factor hASH-1 and MASH-1.

Authors:  I Yoshida; S Koide; S I Hasegawa; A Nakagawara; A Tsuji; Y Matsuda
Journal:  Biochem J       Date:  2001-12-15       Impact factor: 3.857

5.  Kinetics of albumin- and alpha-fetoprotein-production during rat liver development.

Authors:  Abderrahim Elmaouhoub; József Dudas; Giuliano Ramadori
Journal:  Histochem Cell Biol       Date:  2007-09-19       Impact factor: 4.304

6.  Hepatoblast and mesenchymal cell-specific gene-expression in fetal rat liver and in cultured fetal rat liver cells.

Authors:  Tümen Mansuroglu; József Dudás; Abderrahim Elmaouhoub; Tobias Z Joza; Giuliano Ramadori
Journal:  Histochem Cell Biol       Date:  2009-04-19       Impact factor: 4.304

7.  PACE4-based molecular targeting of prostate cancer using an engineered ⁶⁴Cu-radiolabeled peptide inhibitor.

Authors:  Frédéric Couture; Christine Levesque; Véronique Dumulon-Perreault; Samia Ait-Mohand; François D'Anjou; Robert Day; Brigitte Guérin
Journal:  Neoplasia       Date:  2014-08       Impact factor: 5.715

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.